Rezolute (RZLT) Debt to Equity (2011 - 2021)

Rezolute's (RZLT) quarterly Debt to Equity came in at $0.06 in Q1 2021, up 261919.96% quarter-over-quarter from $0.0 in Q4 2017.

Rezolute (RZLT) Debt to Equity (2011 - 2021) Analysis & Trends

Rezolute has disclosed Debt to Equity across 8 years of filings, most recently posting $0.06 for Q1 2021.

Debt to Equity for Q1 2021 came in at $0.06, changed N/A year-over-year; the trailing twelve-month figure through Mar 2021 was $0.06 (changed N/A YoY), and the FY2017 annual result was $0.0, down 94.94% from the prior year.
Debt to Equity came in at $0.06 for Q1 2021 at Rezolute, up from $0.0 in the prior quarter.
In the past five years, Debt to Equity ranged from a high of $0.06 in Q1 2021 to a low of $0.0 in Q4 2017.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt/Equity (Qtr)
1	Alterity Therapeutics	814,307.08 Bn	814,307.05 Bn	-	-
2	Belite Bio	55,320.00 Bn	55,320.00 Bn	-	-
3	Quantum Biopharma	17,149.72 Bn	17,149.72 Bn	-	-
4	Legend Biotech	3,590.00 Bn	3,589.71 Bn	242.10 Mn	0.32
5	Akari Therapeutics	1,650.72 Bn	1,650.72 Bn	-	-
6	Evaxion A	1,522.09 Bn	1,522.07 Bn	-	-
7	Psyence Biomedical	229.39 Bn	229.38 Bn	-	-
8	Vertex Pharmaceuticals	113.09 Bn	105.85 Bn	2.59 Bn	-
9	Abivax	90.15 Bn	90.15 Bn	-	-
10	Rezolute	415.38 Mn	415.38 Mn	-	-

Historic Data

Download Data

Date	Value
Mar 31, 2021	0.06
Dec 31, 2017	0.00
Sep 30, 2017	0.00
Jun 30, 2017	0.00
Mar 31, 2017	0.00
Dec 31, 2016	0.00
Sep 30, 2016	0.00
Jun 30, 2016	0.00
Mar 31, 2016	0.01
Dec 31, 2015	0.00
Sep 30, 2015	0.00
Jun 30, 2015	0.00
Dec 31, 2014	0.14
Sep 30, 2014	0.08
Jun 30, 2014	0.01
Mar 31, 2014	0.33
Dec 31, 2013	-0.24
Sep 30, 2013	-0.20
Jun 30, 2013	-0.04
Mar 31, 2013	-0.15